We are live on ! Find out more
RSCM

Rock Springs Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 93.03%
This Fund
S&P 500
This Quarter Est. Return
-14.64%
1 Year Est. Return
+93.03%
3 Year Est. Return
+228.43%
5 Year Est. Return
+368.14%
10 Year Est. Return
+4,607.77%
AUM
$1.19B
AUM Growth
-$126M
Cap. Flow
+$122M
Cap. Flow %
10.23%
Top 10 Hldgs %
29.08%
Holding
134
New
12
Increased
77
Reduced
4
Closed
6

Top Buys

Rank Stock Value
1
BMY icon
Bristol-Myers Squibb
BMY
+$10.7M
2
WBA
Walgreens Boots Alliance
WBA
+$9.86M
3
ALKS icon
Alkermes
ALKS
+$7.68M
4
ANAC
ANACOR PHARMACEUTICALS INC COM
ANAC
+$7.42M
5
RDUS
Radius Health, Inc.
RDUS
+$7.3M

Top Sells

Rank Stock Value
1
IDXX icon
Idexx Laboratories
IDXX
+$9.3M
2
RLYP
RELYPSA INC COM
RLYP
+$7.14M
3
ABBV icon
AbbVie
ABBV
+$5.18M
4
DYAX
DYAX CORPORATION
DYAX
+$4.67M
5
TVTX icon
Travere Therapeutics
TVTX
+$2.33M

Sector Composition

Rank Sector Weight
1 Healthcare 77.87%
2 Financials 3.87%
3 Industrials 0.53%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SYBX
126
DELISTED
Synlogic
SYBX
$656K 0.06%
1,429
– –
ABBV icon
127
AbbVie
ABBV
$435B
– –
-87,500
Closed -$5.18M
IDXX icon
128
Idexx Laboratories
IDXX
$46.2B
– –
-127,500
Closed -$9.3M
SRPT icon
129
CALL
Sarepta Therapeutics
SRPT
$1.77B
– –
-53,300
Closed -$2.06M
PETX
130
DELISTED
Aratana Therapeutics, Inc.
PETX
– –
-43,445
Closed -$242K
RLYP
131
DELISTED
RELYPSA INC COM
RLYP
– –
-252,000
Closed -$7.14M
DYAX
132
DELISTED
DYAX CORPORATION
DYAX
– –
-124,000
Closed -$4.67M
2 3 4 5
6

Similar funds

ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $1.68B AUM 40.61% 1-Year Est. Return
JIP
Jaffetilchin Investment Partners Tampa, Florida $1.68B AUM 22.81% 1-Year Est. Return
II
Inspire Investing Meridian, Idaho $1.71B AUM 31.76% 1-Year Est. Return

Rock Springs Capital Management's Q1 2016 Portfolio in Review

As of Q1 2016, Rock Springs Capital Management held 134 positions worth $1.19B, down 9.6% from $1.32B the previous quarter. Its ten largest holdings account for 29% of the portfolio.

Rock Springs Capital Management deployed $122M of net new capital in Q1 2016, opening 12 new positions and adding to 77 existing holdings. Its largest new stake was Bristol-Myers Squibb: 170,000 shares worth $10.9M.

By sector, the portfolio is most concentrated in Healthcare at 78% of assets, up from 77% a quarter earlier, followed by Financials and Industrials.

On the sell side, the largest reduction was Travere Therapeutics, an estimated $2.33M trimmed.

  • Rock Springs Capital Management's largest Q1 2016 buy was Bristol-Myers Squibb: 170,000 shares worth $10.9M.
  • Rock Springs Capital Management added most to ANACOR PHARMACEUTICALS INC COM in Q1 2016, an estimated $7.42M increase.
  • Rock Springs Capital Management's biggest Q1 2016 reduction was Travere Therapeutics, cutting an estimated $2.33M.
  • Rock Springs Capital Management fully exited Idexx Laboratories in Q1 2016, selling an estimated $9.3M.
  • Rock Springs Capital Management's ten largest holdings make up 29% of its $1.19B portfolio in Q1 2016.
  • Rock Springs Capital Management opened 12 new positions and closed 6 in Q1 2016.
  • Rock Springs Capital Management's portfolio value fell 9.6% quarter-over-quarter to $1.19B.

Based on Rock Springs Capital Management's 13F filing for Q1 2016, filed 16 May 2016.